Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Venlafaxine (compound)


PubChem
Name: venlafaxine
PubChem Compound ID: 11846745
Molecular formula: C17H28ClNO2
Molecular weight: 313.862 g/mol
DrugBank
Identification
Name: venlafaxine
Name (isomeric): DB00285
Drug Type: small molecule
Synonyms:
Venlafaxina [INN-Spanish]; Venlafaxine [INN:Ban]; Venlafaxinum [INN-Latin]
Brand: Effexor, Effexor XR, Elafax
Category: Antidepressants, Analgesics, Antidepressive Agents, Second-Generation, Serotonin Uptake Inhibitors
CAS number: 93413-69-5
Pharmacology
Indication: For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, and vasomotor symptoms in women with breast cancer and in postmenopausal women.
Pharmacology: Venlafaxine, an antidepressant agent structurally and pharmacologically unrelated to other antidepressants and agents used to treat generalized anxiety disorder, is used to treat melancholia, generalized anxiety disorder (GAD), panic disorder, post-traumatic stress disorder, and hot flashes in breast cancer survivors.
Mechanism of Action:
The exact mechanism of action of venlafaxine is unknown, but appears to be associated with the its potentiation of neurotrasmitter activity in the CNS. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), inhibit the reuptake of both serotonin and norepinephrine with a potency greater for the 5-HT than for the NE reuptake process. B...
show more »
Absorption: Bioavailability is 45% following oral administration.
Protein binding: venlafaxine, 27%; ODV, 30%
Biotransformation: Undergoes extensive first pass metabolism in the liver to its major, active metabolite, ODV, and two minor, less active metabolites, N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. Formation of ODV is catalyzed by cytochrome P450 (CYP) 2D6, whereas N-demethylation is catalyzed by CYP3A4, 2C19 and 2C9. ODV possesses antidepressant activity that is comparable to that of venlfaxine.
Route of elimination: Renal elimination of venlafaxine and its metabolites is the primary route of excretion.
Half Life: 5 hours
Clearance: 1.3 +/- 0.6 L/h/kg
Toxicity: Most patients overdosing with venlafaxine develop only mild symptoms. However, severe toxicity is reported with the most common symptoms being CNS depression, serotonin toxicity, seizure, or cardiac conduction abnormalities. Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the tricyclic antidepressants than the SSRIs. Doses of 900 mg or more are likely to cause moderate toxicity. Deaths have been reported following large doses.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Avoid St.John's Wort.
Avoid alcohol.
Take with food.
Drug interaction:
FosamprenavirFosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed.
ChlorpromazineChlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed.
KetoconazoleKetoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.
TramadolIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
MeperidineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
show more »

Targets


Enzymes


Transporters